Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron that just showed positive results from a ...

Most developers use arrays, lists, and hash maps daily — but these five wild data structures push performance to another ...

Lukas Maar (Graz University of Technology), Jonas Juffinger (Graz University of Technology), Thomas Steinbauer (Graz University of Technology), Daniel Gruss (Graz University of Technology), Stefan ...

Scientists have observed the largest-known rotating structure in the cosmos - a gargantuan thread-like assemblage of hundreds ...

Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...

Discover why Southern Company offers 12% upside and a 3.5% yield. Explore Q3 results, growth from data centers, and dividend ...

A bus from NEPA headed south and rolled through what’s become knows as “Data Center Alley.” The excursion on Wednesday, ...

A recent Bloomberg Intelligence study found that buyside European equity traders want lighter regulation, more retail flow ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

Investing.com -- Structure Therapeutics Inc ADR (NASDAQ:GPCR) stock soared 28.8% in premarket trading Monday after the company announced positive topline data from its ACCESS clinical program for ...

Structure Therapeutics stock soars 103% as its oral obesity drug aleniglipron shows strong Phase 2b weight-loss results.

Venkata Surya Bhavana Harish Gollavilli, is a technology leader and strategist, currently serving as a Software Development ...